November 15, 2025 • 6 mins
# Navigating Ozempic Podcast: Breaking News on GLP-1 Medications and Healthcare Access
In this eye-opening episode of Navigating Ozempic, we explore groundbreaking developments in the world of GLP-1 medications. Learn about the White House's historic agreement with pharmaceutical companies to reduce costs of Ozempic, Wegovy, and similar medications through Medicare and Medicaid reforms coming in 2026-2027.
Discover exciting new research showing how semaglutide helps dialysis patients qualify for kidney transplants, potentially reduces colorectal cancer mortality, and provides cardiovascular protection. We also discuss Novo Nordisk's promising oral semaglutide pill that achieved 16.6% average weight loss in clinical trials.
From potential applications for long COVID to the importance of resistance training while using these medications, this episode offers valuable insights for patients, healthcare providers, and anyone interested in the intersection of obesity treatment, healthcare policy, and scientific innovation. Stay informed about these revolutionary medications that are transforming approaches to chronic disease management.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
In this eye-opening episode of Navigating Ozempic, we explore groundbreaking developments in the world of GLP-1 medications. Learn about the White House's historic agreement with pharmaceutical companies to reduce costs of Ozempic, Wegovy, and similar medications through Medicare and Medicaid reforms coming in 2026-2027.
Discover exciting new research showing how semaglutide helps dialysis patients qualify for kidney transplants, potentially reduces colorectal cancer mortality, and provides cardiovascular protection. We also discuss Novo Nordisk's promising oral semaglutide pill that achieved 16.6% average weight loss in clinical trials.
From potential applications for long COVID to the importance of resistance training while using these medications, this episode offers valuable insights for patients, healthcare providers, and anyone interested in the intersection of obesity treatment, healthcare policy, and scientific innovation. Stay informed about these revolutionary medications that are transforming approaches to chronic disease management.
Some great Deals https://amzn.to/49SJ3Qs
For more check out http://www.quietplease.ai
This content was created in partnership and with the help of Artificial Intelligence AI
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
Speaker 1 (00:00):
Welcome back to Navigating Ozempic, the podcast where we bring
listeners the most timely, relevant and impactful news shaping the
world of ozempic and its broader class of medications. Today
is November fifteenth, twenty twenty five, and the last several
days have brought major headlines and new scientific insights. Whether
you are a patient, clinician, or someone interested in the
(00:22):
intersection of science, health policy, and daily life, there is
a lot to unpack. Let's dive into the heart of
the news. One of the most talked about developments this
week is a blockbuster announcement out of Washington. The White House,
in partnership with pharmaceutical giants Eli, Lilly and Notho Nordisk,
has announced a far reaching deal to dramatically lower the
(00:43):
costs of glp ie medications, which include ozempic, wagov, Munjaro,
and zep bound. This agreement is poised to bring Medicare
and Medicaid coverage to these obesity and diabetes medications for
a flat monthly price, make life changing drugs more accessible
for millions. Under the new framework, the Medicare price for
(01:05):
these drugs will be set at two hundred and forty
five dollars per month, and Medicare will for the first
time cover where GOV and ZEP bound for patients with
obesity and related comorbidities, with beneficiaries paying just a fifty
dollar copey. State Medicaid programs will also have access at
these new lower prices. The launch is expected in May
(01:27):
twenty twenty six for Medicaid and in January twenty twenty
seven for Medicare. While the program is still in development,
its potential impact on affordability and access cannot be overstated. NCPA,
the National Community Pharmacists Association, is working alongside the administration
(01:48):
to ensure patients can obtain these medications through local pharmacies
with fair reimbursement for pharmacists. Lowering the cost barrier could
reshape not just healthcare budgets, but the lives of Americans
struggling with chronic metabolic diseases, according to NCPA reports and
recent statements from the White House. Turning to breaking research,
(02:10):
Saint Louis University School of Medicine and SSM Health have
published a new study in clinical transplantation that could be
a game changer for those living with N stage kidney disease.
This research focused on dialysis patients who are often denied
kidney transplants due to obesity related surgical risks. The investigators
(02:30):
treated patients with semaglutide, the active ingredient in nozenpic, and
found that participants lost an average of twenty point five
pounds in one year. Remarkably, nearly half of the patients
who were previously too overweight to qualify for a transplant
were reactivated on the weight list. Additionally, more than a
third of insulin dependent patients were able to discontinue insulin
(02:53):
therapy entirely. The studies authors highlight that these results provide
a promising non surgical pathway for weight resin reduction, offering
hope to a patient population previously short on options. While
some patients did discontinue treatment due to side effects, the
majority found the drug tolerable, especially with integrated multidisciplinary care
(03:14):
involving nutrition advice and follow up. Lead researcher Francis Wade
Meters dot D emphasized that this new era of effective,
well tolerated weight loss drugs could transform transplant medicine as
(03:34):
we know it. In the oncology realm, Medical News Today
reports on a newly published study in Cancer Investigation suggesting
that GLP one drugs like ozempic could actually lower the
risk of death in people with chilorectal cancer. Analysts looked
at over sixty eight hundred adults with a diagnosis of
colon cancer. The findings are striking. Among those taking GLP
(03:57):
one drugs, the five year mortality risk was fifteen and
a half percent, compared to thirty seven point one percent
for those not on these medications. The survival advantage appeared
strongest in patients with higher body mass indexes, underscoring the
interconnected biology of obesity, metabolic health, and cancer. Commentators like
(04:19):
doctor Anton Bilchick of Providence Saint John's Cancer Institute note
that these drugs may have direct anti cancer effects, possibly
influencing immune function and inflammation, in addition to their well
established benefits on weight. Experts agree that randomized trials are
the next critical step, but this research opens the intriguing
door that the scope of ozempic and similar medications could
(04:43):
ultimately reach far beyond weight loss and diabetes. Other studies
released this week add to the growing evidence of ozepic's
protective effects on the heart. According to Science Daily, new
findings from the Technical University of Munich and Harvard Medical
School show that semaglutide, the compound found in ozepic, as
(05:03):
well as tear zeppatide, reduces the risk of major heart
events in people with obesity or diabetes. This bolsters data
that these drubs not only treat chronic conditions, but can
actually help prevent heart attacks and strokes, marking a paradigm
shift in cardiovascular prevention. If the thought of self injecting
medication is a barrier, groundbreaking news from Popular Mechanics a
(05:26):
Novo Nordisk's own later study may change that. The pharmaceutical
company has unveiled results from a seventy one week clinical
trial on an oral version of semaglutide, the daily pill
form of the active ingredient in ozempic and weadovi. This
oral version produced an average weight loss of sixteen point
six percent compared to two point seven percent for a placebo,
(05:49):
with about a third of users achieving more than twenty
percent weight loss. The pill appears to be almost as
effective as the weakly injected version, and pending regulatory approved
could make access to this class of drugs easier and
more appealing for millions. This innovation would provide flexibility and
could further fuel the rise in prescriptions. Beyond weight loss,
(06:12):
the conversation about GLP one drugs like ozepic is evolving
to include their broader health impacts, as explored this week
by UC Davis. Health experts point out that as GLP
one receptor agonists reshape obesity and unnatural risk
Welcome back to Navigating Ozempic, the podcast where we bring
listeners the most timely, relevant and impactful news shaping the
world of ozempic and its broader class of medications. Today
is November fifteenth, twenty twenty five, and the last several
days have brought major headlines and new scientific insights. Whether
you are a patient, clinician, or someone interested in the
(00:22):
intersection of science, health policy, and daily life, there is
a lot to unpack. Let's dive into the heart of
the news. One of the most talked about developments this
week is a blockbuster announcement out of Washington. The White House,
in partnership with pharmaceutical giants Eli, Lilly and Notho Nordisk,
has announced a far reaching deal to dramatically lower the
(00:43):
costs of glp ie medications, which include ozempic, wagov, Munjaro,
and zep bound. This agreement is poised to bring Medicare
and Medicaid coverage to these obesity and diabetes medications for
a flat monthly price, make life changing drugs more accessible
for millions. Under the new framework, the Medicare price for
(01:05):
these drugs will be set at two hundred and forty
five dollars per month, and Medicare will for the first
time cover where GOV and ZEP bound for patients with
obesity and related comorbidities, with beneficiaries paying just a fifty
dollar copey. State Medicaid programs will also have access at
these new lower prices. The launch is expected in May
(01:27):
twenty twenty six for Medicaid and in January twenty twenty
seven for Medicare. While the program is still in development,
its potential impact on affordability and access cannot be overstated. NCPA,
the National Community Pharmacists Association, is working alongside the administration
(01:48):
to ensure patients can obtain these medications through local pharmacies
with fair reimbursement for pharmacists. Lowering the cost barrier could
reshape not just healthcare budgets, but the lives of Americans
struggling with chronic metabolic diseases, according to NCPA reports and
recent statements from the White House. Turning to breaking research,
(02:10):
Saint Louis University School of Medicine and SSM Health have
published a new study in clinical transplantation that could be
a game changer for those living with N stage kidney disease.
This research focused on dialysis patients who are often denied
kidney transplants due to obesity related surgical risks. The investigators
(02:30):
treated patients with semaglutide, the active ingredient in nozenpic, and
found that participants lost an average of twenty point five
pounds in one year. Remarkably, nearly half of the patients
who were previously too overweight to qualify for a transplant
were reactivated on the weight list. Additionally, more than a
third of insulin dependent patients were able to discontinue insulin
(02:53):
therapy entirely. The studies authors highlight that these results provide
a promising non surgical pathway for weight resin reduction, offering
hope to a patient population previously short on options. While
some patients did discontinue treatment due to side effects, the
majority found the drug tolerable, especially with integrated multidisciplinary care
(03:14):
involving nutrition advice and follow up. Lead researcher Francis Wade
Meters dot D emphasized that this new era of effective,
well tolerated weight loss drugs could transform transplant medicine as
(03:34):
we know it. In the oncology realm, Medical News Today
reports on a newly published study in Cancer Investigation suggesting
that GLP one drugs like ozempic could actually lower the
risk of death in people with chilorectal cancer. Analysts looked
at over sixty eight hundred adults with a diagnosis of
colon cancer. The findings are striking. Among those taking GLP
(03:57):
one drugs, the five year mortality risk was fifteen and
a half percent, compared to thirty seven point one percent
for those not on these medications. The survival advantage appeared
strongest in patients with higher body mass indexes, underscoring the
interconnected biology of obesity, metabolic health, and cancer. Commentators like
(04:19):
doctor Anton Bilchick of Providence Saint John's Cancer Institute note
that these drugs may have direct anti cancer effects, possibly
influencing immune function and inflammation, in addition to their well
established benefits on weight. Experts agree that randomized trials are
the next critical step, but this research opens the intriguing
door that the scope of ozempic and similar medications could
(04:43):
ultimately reach far beyond weight loss and diabetes. Other studies
released this week add to the growing evidence of ozepic's
protective effects on the heart. According to Science Daily, new
findings from the Technical University of Munich and Harvard Medical
School show that semaglutide, the compound found in ozepic, as
(05:03):
well as tear zeppatide, reduces the risk of major heart
events in people with obesity or diabetes. This bolsters data
that these drubs not only treat chronic conditions, but can
actually help prevent heart attacks and strokes, marking a paradigm
shift in cardiovascular prevention. If the thought of self injecting
medication is a barrier, groundbreaking news from Popular Mechanics a
(05:26):
Novo Nordisk's own later study may change that. The pharmaceutical
company has unveiled results from a seventy one week clinical
trial on an oral version of semaglutide, the daily pill
form of the active ingredient in ozempic and weadovi. This
oral version produced an average weight loss of sixteen point
six percent compared to two point seven percent for a placebo,
(05:49):
with about a third of users achieving more than twenty
percent weight loss. The pill appears to be almost as
effective as the weakly injected version, and pending regulatory approved
could make access to this class of drugs easier and
more appealing for millions. This innovation would provide flexibility and
could further fuel the rise in prescriptions. Beyond weight loss,
(06:12):
the conversation about GLP one drugs like ozepic is evolving
to include their broader health impacts, as explored this week
by UC Davis. Health experts point out that as GLP
one receptor agonists reshape obesity and unnatural risk
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.